A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MEHD7945A Administered Intravenously to Patients With Locally Advanced or Metastatic Epithelial Tumors.

Trial Profile

A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MEHD7945A Administered Intravenously to Patients With Locally Advanced or Metastatic Epithelial Tumors.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Duligotuzumab (Primary)
  • Indications Carcinoma; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 04 May 2016 Planned End Date changed from 1 Feb 2016 to 1 Aug 2017.
    • 04 May 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Aug 2017.
    • 01 Jul 2015 Planned End Date changed from 1 Jan 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top